Skip to main content
OpenTrials
Completed

NCT Number: NCT06412783

Population-based Investigation of Aneurysm Incidence

Most intracranial aneurysms are found accidentally in neurovascular imaging. And these inspection methods are limited by the problems of instrument fixation, radiation, time-consuming, contrast agent toxicity and so on. At present, blood test is an ideal alternative method for early diagnosis. Compared with imaging examination, it is economical, general screening and convenient. Blood test is simple to operate, easy to be accepted by patients, and less invasive. Early screening of aneurysms can be performed.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Intracranial Aneurysm Aneurysm Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Intracranial Arterial Diseases Nervous System Diseases Vascular Diseases

Age range

35 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Capital Medical University Affiliated Beijing Tiantan Hospital

Beijing, Beijing Municipality, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 35-75
  • Individuals with normal cognitive and communication abilities
  • No serious complications, such as uncontrolled hypertension, diabetes or other chronic diseases that may affect the test results.
  • Basic blood test is normal or close to normal range.

Exclusion criteria

  • Pregnancy
  • Severe heart disease, renal insufficiency, liver dysfunction and other major diseases.
  • In the past 6 months, there were strokes, or other types of intracranial tumors, infections and other diseases that may affect the screening results.
  • There are metal implants, including dentures, pacemakers, etc.
  • Using or recently used drugs that may affect blood biomarkers ( such as anticoagulant drugs, immunosuppressive agents, etc. ).
  • There are serious mental illness or cognitive dysfunction, such as claustrophobia, unable to cooperate with the completion of the test.
  • It is currently participating in other clinical trials or has participated in other clinical trials in the past 3 months.

Treatment and study plan

Blood test

Diagnostic Test

performing blood tests on the participants for specific markers.

Primary outcomes

  1. Specific markers are detected

    Time frame: 1hours after blood collection

    oleic acid, arachidonic acid, docasa-hexaenoic acid, interleukin 1β， interleukin 1ra, tumor necrosis factors, SOD3, PPIA, S100A8, S100A9, MPO, APOA4, THBS1.

Sponsors and collaborators

Lead sponsor

Beijing Tiantan Hospital

Other

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2025
First posted
May 14, 2024
Registry last updated
May 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.